TScan Therapeutics

Company snapshot

TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. TScan Therapeutics is a fully integrated, next-generation TCR-T cell therapy company. Founded in 2018, TScan’s platform was developed by Stephen Elledge, Ph.D., and Tomasz Kula, Ph.D., at Brigham and Women’s Hospital and Harvard Medical School. TScan’s transfo

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for TScan Therapeutics. Not investment advice.

• Peer + 0 momentum

  ADC Therapeutics

  TA overlap score 26

• Peer + 0 momentum

  Astellas Pharma

  TA overlap score 24.4

• Peer + 0 momentum

  Prime Medicine

  TA overlap score 23.4

• Peer + 0 momentum

  IDEAYA Biosciences

  TA overlap score 22.8

• Peer + 0 momentum

  ALX ONCOLOGY HOLDINGS

  TA overlap score 22.6

• Peer + 0 momentum

  Pyxis Oncology

  TA overlap score 21.6

• Peer + 0 momentum

  PURPLE BIOTECH

  TA overlap score 20.6

Recent activity

Latest pipeline, patent, and corporate events for TScan Therapeutics.

1. Jun 8, 2026 Clinical update

   SOC + TSC-100 — Phase 1

2. Jun 5, 2026 Clinical update

   Tcrx T cell — Phase 1

3. Jun 5, 2026 Clinical update

   KXV01 TCR Lentinvivo Injection — Phase 1

4. Jun 5, 2026 Clinical update

   KSX01-TCRT injection — Phase 1

5. Jun 5, 2026 Clinical update

   KSV01 Injection — Phase 1

View all clinical trial activity →

• What is TScan Therapeutics?

  TScan Therapeutics is a biotech organization headquartered in Waltham, USA. It trades on NYSE under ticker TCRX. Primary therapeutic focus areas include TCR-T Cells, B-ALL, Solid Tumor, Non-Hodgkin Lymphoma, Advanced Solid Tumors. NovaPharmaNews links 9 clinical program(s), 0 dru

• Is TScan Therapeutics publicly traded?

  Yes. TScan Therapeutics is listed with ticker TCRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does TScan Therapeutics develop or market?

  We link 5 drug profile(s) where TScan Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tscan-therapeutics#company-drugs.

• What are the latest developments for TScan Therapeutics?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does TScan Therapeutics focus on?

  TScan Therapeutics focuses on TCR-T Cells, B-ALL, Solid Tumor based on our analysis of their pipeline programs and drug development activities.